Post-natal Steroid Exposure in Very Low Birthweight Neonates and Associations with Acute Kidney Injury

doi:10.21203/rs.3.rs-3715962/v1

Download PDF

Article

Post-natal Steroid Exposure in Very Low Birthweight Neonates and Associations with Acute Kidney Injury

https://doi.org/10.21203/rs.3.rs-3715962/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 23 May, 2024

Read the published version in Journal of Perinatology →

You are reading this latest preprint version

Objective:

The relationship between adrenal insufficiency (AI), post-natal steroids (PNS) and neonatal acute kidney injury (AKI) remains understudied. We aimed to investigate associations between PNS and AKI in very low birthweight (VLBW) neonates, hypothesizing PNS is independently associated with reduced AKI.

Study Design:

We conducted a single-center retrospective review of VLBW infants. Comparisons were made between those with and without PNS exposure. Associations between PNS exposure and AKI were evaluated using generalized linear mixed-modeling adjusted for confounders.

Result:

Of 567 neonates, 97 (17.1%) were exposed to PNS and 130 (22.9%) experienced AKI. Infants with PNS had lower gestational age, birthweight, Apgar scores, and experienced more AI versus those without PNS (all p <0.05). PNS was independently associated with AKI (aRR 1.72, 95% CI 1.09 – 2.72).

Conclusion:

PNS exposure is independently associated with increased AKI in VLBW neonates. Further analysis is needed to investigate the role of AI and AKI.

Health sciences/Diseases/Kidney diseases/Acute kidney injury

Health sciences/Diseases/Endocrine system and metabolic diseases

Health sciences/Risk factors

Health sciences/Health care/Therapeutics/Drug therapy

Health sciences/Health care/Paediatrics

Acute kidney injury (AKI) occurs commonly in the neonatal intensive care unit (NICU) and is associated with increased morbidity and mortality. In the Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates (AWAKEN) study, Jetton et al. found that AKI in neonates was independently associated with both increased mortality (9.7 vs. 1.4%, p < 0.01; aOR 4.6, 95% CI 2.5–8.3; p < 0.01) as well as increased length of stay (adjusted parameter estimate 8.8 days, 95% CI 6.1–11.5; p < 0.01) [1]. Furthermore, survivors of neonatal AKI are at increased risk for the development of chronic kidney disease (CKD) [2].

Extremely premature and very low birthweight (VLBW, i.e., birthweight < 1 500 grams) infants are particularly susceptible to AKI. With up to 60% of nephrogenesis occurring in the third trimester, premature birth alters final nephron number significantly, increasing risk of AKI in this population [3, 4]. In the AWAKEN study, incidence of AKI in infants born at less than 29 weeks of gestation was nearly 48% [1]. Other authors have similarly found that incidence of AKI differs significantly by gestational age (GA), with AKI rates being significantly higher with decreased GA and birthweight (BW) [5]. AKI has also been found to be associated with extrarenal outcomes including intraventricular hemorrhage (IVH) [6–8], increased length of mechanical ventilation and bronchopulmonary dysplasia (BPD) in VLBW neonates [9, 10].

Corticosteroids are utilized in VLBW infants for pressor-resistant hypotension, adrenal insufficiency (AI), pulmonary inflammation, air way edema in preparation for extubation, and systemic inflammatory response-type syndromes. Small single-center investigations have suggested that some AKI in VLBW neonates may be due to glucocorticoid-responsive circulatory collapse and relative innate AI, with resolution of AKI upon initiation of steroids, particularly hydrocortisone [11]. To our knowledge, this association between corticosteroids and AKI has not been investigated in a large cohort of VLBW neonates.

To address this gap in knowledge, we performed a detailed evaluation of post-natal steroid (PNS) exposure and AKI in VLBW neonates. The objectives of this study are to describe the incidence of AKI in VLBW infants stratified by PNS receipt and investigate potential associations between PNS treatment and AKI with a specific evaluation examining associations between hydrocortisone and AKI. We hypothesized that in VLBW infants, PNS would be independently associated with reduced incidence of AKI.

Study Population

We conducted a retrospective chart review of VLBW infants born between January 1, 2018, and December 31, 2020, admitted to the Medical University of South Carolina (MUSC) NICU within 48 hours of delivery. Infants were identified using the MUSC Internal Perinatal Information System database. We excluded infants who: died or were transitioned to palliative care courses within 48 hours of admission, had lethal chromosomal anomalies, had known congenital kidney or urinary tract abnormalities, or had less than two measured serum creatinine values. This protocol was approved by the MUSC Institutional Review Board with a waiver of informed consent.

Data Collection

Demographic information collected included GA, BW, Apgar scores, size for GA (small for gestational age (SGA), defined as < 10th percentile for age and large for gestational age (LGA), defined as > 90th percentile [12]), sex, race, and AI (defined as presence of diagnosis in discharge diagnoses). Potential confounding factors for AKI that were collected included hypotension, caffeine exposure, patent ductus arteriosus (PDA), sepsis, mechanical ventilation, necrotizing enterocolitis, and nephrotoxic medication exposure [13]. For patients without AKI, we investigated these confounders if present at any time during their hospital stay. For patients with AKI, we screened for these confounders both 48 hours before diagnosis of AKI as well as throughout the AKI episode.

Study data were collected and managed using REDCap electronic data capture tools hosted at MUSC [14, 15].

Exposure: Post-natal Corticosteroids

The exposure of interest was PNS receipt. If AKI occurred, PNS was considered present only if it was prescribed prior to the first AKI episode. PNS included dexamethasone, prednisone, hydrocortisone, methylprednisolone, and fludrocortisone. Antenatal steroid exposure was excluded.

Outcome: Neonatal Acute Kidney Injury

Our outcome of interest was neonatal AKI, diagnosed and staged based on severity using the modified, neonatal Kidney Disease: Improving Global Outcomes (KDIGO) serum creatinine criteria [16] (Supplemental Table 1). Only information regarding the first episode of AKI was included. Recurrent episodes of AKI were not evaluated. Notably, AKI diagnosis on the discharge summary, indicating AKI was detected by the neonatal care team during the hospitalization, was also collected, however our analysis and AKI stratification was based on presence or absence of AKI as determined by the research team.

Statistical Analysis

Comparisons were made between those with and without PNS exposure as well as with and without AKI using chi-square, Student’s t, and Wilcoxon rank sum tests as appropriate. Categorical data are expressed as frequency (proportions). Continuous data are expressed as median [interquartile range] for non-normally distributed data and mean ± standard deviation for normally distributed data.

Associations between PNS exposure and AKI were evaluated using bivariate and generalized multivariable mixed modeling adjusted for significant confounders for AKI. Outcomes were presented as unadjusted and adjusted relative risks with 95% confidence interval (CI). In multivariable analysis, potential confounders were entered into the model as a covariate if they were statistically significant in the baseline demographic and characteristic analysis (p < 0.05) or were established confounders for AKI and found to be associated with AKI in our cohort in bivariate analysis (p < 0.05). Adjusted models included PNS, SGA, BW, APGAR scores (1 minute), AI, caffeine exposure, hypotension, PDA, sepsis, mechanical ventilation, necrotizing enterocolitis, and nephrotoxic medication exposure. A secondary, subgroup analysis between solely HC exposure and AKI was also performed using the same mixed modeling and controlling for the same significant confounders. All p-values < 0.05 were considered statistically significant.

All analyses were performed using SASⒸ (version 9.4; SAS institute, Cary, NC, USA). All results are reported in accordance with the STROBE guidelines [17].

Subject Selection

There were 761 VLBW infants born at MUSC or admitted to MUSC NICU within 48 hours of life between 1/1/2018–12/31/2020. After exclusion, 567 patients were included in our analysis (Fig. 1).

Postnatal Steroid Exposure

Out of 567 subjects included, 97 (17.1%) received PNS. Subjects treated with PNS had significantly lower GA (PNS exposure: 25.9 ± 2.4 weeks vs. no PNS exposure: 28.9 ± 2.6 weeks), BW (PNS exposure: 813 ± 244 grams vs. no PNS exposure: 1 125 ± 271 grams), and Apgar scores at 1 and 5 minutes (PNS exposure: 3 [1, 5] vs. no PNS exposure: 5 [3, 7] and PNS exposure: 6 [5, 7] vs. no PNS exposure: 8 [7, 9], respectively) (p < 0.01 for all) and were significantly more likely to die prior to discharge (PNS exposure: 17 (18%) vs. no PNS exposure: 20 (4.3%), p < 0.01) (Table 1). Notably, AI was diagnosed more frequently in those with PNS exposure than in those without PNS exposure (PNS exposure: 42 (43%) vs. no PNS exposure: 16 (3.4), p < 0.01).

Table 1

Baseline Demographics and Characteristics of Infants with Post-natal Steroid Exposure versus no Post-natal Steroid Exposure Legend: Categorical variables are presented as n (%), mean ± standard deviation or median [Q1, Q3]. DC: Discharge. AA: African American. °p-values from chi-square test, Student’s t-test, or Wilcoxon Rank Sum test. *Excludes antenatal steroid exposure. Includes post-natal steroid exposure prior to first episode of AKI.
Baseline Demographics and Characteristics		Overall (n = 567)	PNS Exposure* (n = 97, 17.1%)	No PNS Exposure* (n = 470, 82.9%)	p-value°
GA (weeks)		28.4 ± 2.8	25.9 ± 2.4	28.9 ± 2.6	< .001
Birthweight (grams)		1071 ± 291	813 ± 244	1125 ± 271	< .001
Apgar	1 minute	5 [3, 7]	3 [1, 5]	5 [3, 7]	< .001
Apgar	5 minutes	8 [6, 8]	6 [5, 7]	8 [7, 9]	< .001
Size for GA	Small	171 (30)	23 (24)	148 (32)	0.126
	Average	381 (67)	73(75)	308 (66)	0.067
	Large	14 (2.5)	1 (1)	13 (2.8)	0.315
Male		275 (49)	54 (56)	221 (47)	0.121
Race	Caucasian	172 (30)	26 (27)	146 (31)	0.406
	Black/AA	322 (57)	56 (58)	266 (57)	0.837
	Hispanic	30 (5.3)	5 (5.2)	25 (5.3)	0.948
	Other	39 (6.9)	8 (8.3)	31 (6.6)	0.559
Died prior to discharge		37 (6.5)	17 (18)	20 (4.3)	< .001
AKI in DC diagnoses		101 (18)	27 (28)	74 (16)	0.005
Adrenal insufficiency		58 (10)	42 (43)	16 (3.4)	< .001

Acute Kidney Injury

The incidence of AKI in the cohort was 22.9% (N = 130) though only 101 (78%) of these neonates had the diagnosis of AKI recognized during their hospitalization and noted on their discharge summaries. The demographics describing those that did and did not develop AKI are presented in Supplemental Table 2. Those who developed AKI had significantly lower GA (AKI: 26.1 ± 2.4 weeks vs. no AKI: 29.1 ± 2.5 weeks), BW (AKI: 835 ± 246 grams vs. No AKI: 1 142 ± 265 grams), and Apgar scores at 1 and 5 minutes (AKI: 4 [2, 6] vs. no AKI: 5 [3, 7] and AKI: 7 [6, 8] vs. no AKI: 8 [7, 9], respectively) (p < 0.01 for all). Those with AKI were significantly more likely to die prior to discharge (AKI: 24 (19%) vs. no AKI: 13 (3.0%); p < 0.01).

Association between Postnatal Steroid Exposure and Acute Kidney Injury

Table 2 presents the bivariable and multivariable analysis evaluating factors associated with the development of AKI. In bivariable analysis, PNS exposure was found to be associated with increased risk of AKI (RR 1.86, 95% CI 1.35–2.55; p < 0.01) (Table 2). On multivariable analysis, PNS exposure was associated with a 1.72-fold increased adjusted relative risk of developing AKI in our cohort (aRR 1.72 95% CI 1.09–2.72, p = 0.02).

Table 2

Associations between Post-natal Steroid Exposure and Acute Kidney Injury using Multivariable Generalized Linear Mixed Modeling Legend: *Controlled for small for gestational age, birthweight, one-minute Apgar score, death prior to discharge, hypotension, patent ductus arteriosus, sepsis, and mechanical ventilation. **Includes post-natal steroid exposure prior to first episode of AKI. °P-values from bivariate and multivariate generalized mixed modeling.
Characteristic		Unadjusted Bivariate Comparison			Adjusted Multivariate Comparison
Characteristic		Relative Risk (RR)	RR 95% Confidence Interval	p-value°	Adjusted Relative Risk (aRR)*	aRR 95% Confidence Interval	p-value°
Post-natal steroid use**		1.86	(1.35, 2.55)	< .001	1.72	(1.09, 2.72)	0.021
Gestational age (weeks)		0.72	(0.69, 0.76)	< .001	0.91	(0.83, 1.00)	0.058
Small for Gestational Age		0.63	(0.43, 0.93)	0.018	1.01	(0.71, 1.43)	0.962
Apgar	1 minute	0.85	(0.80, 0.91)	< .001	0.99	(0.89, 1.09)	0.777
Apgar	5 minutes	0.85	(0.80, 0.90)	< .001	1.01	(0.90, 1.15)	0.814
Adrenal insufficiency		3.11	(2.34, 4.12)	< .001	1.10	(0.67, 1.81)	0.713
Caffeine		6.99	(2.64, 18.53)	< .001	1.15	(0.40, 3.32)	0.791
Hypotension		4.21	(3.17, 5.59)	< .001	1.64	(1.14, 2.36)	0.001
Patent ductus arteriosus		4.81	(3.30, 7.03)	< .001	1.76	(1.18, 2.64)	0.006
Sepsis		3.97	(3.00, 5.24)	< .001	1.51	(1.06, 2.15)	0.023
Mechanical ventilation		11.52	(5.74, 23.13)	< .001	4.05	(1.87, 8.78)	< .001
Necrotizing enterocolitis		2.33	(1.68, 3.23)	< .001	1.31	(0.79, 2.18)	0.294
Nephrotoxic medication exposure		7.10	(3.19, 15.79)	< .001	1.71	(0.74, 3.98)	0.211

Sub-Analysis: Association between Hydrocortisone Exposure and Acute Kidney Injury

In our cohort, 68 (11.9%) neonates received hydrocortisone. In a secondary sub-analysis, HC appeared to have a protective effect against AKI with the incidence of AKI in neonates treated with HC being 23% and 77% in those without HC exposure (p < 0.01, Table 3). However, after controlling for significant confounders and baseline differences, HC exposure was no longer associated with AKI (aRR 1.51, 95% CI 0.91–2.52, Table 4).

Table 3

Bivariable Association between Acute Kidney Injury and Hydrocortisone Exposure. *Legend: *Includes hydrocortisone exposure prior to first episode of AKI. °P-value from Chi-square test*
Post-Natal Hydrocortisone	AKI (n = 130)	No AKI (n = 437)	p-value°
*Hydrocortisone Exposure (n = 68)**	30 (23.1)	38 (8.7)	< .001
*No Hydrocortisone Exposure (n = 499)**	100 (76.9)	399 (91.3)	< .001

Table 4

Associations between Hydrocortisone Exposure and Acute Kidney Injury using Multivariable Generalized Linear Mixed Modeling.
Characteristic		Unadjusted Relative Risk (RR)	95% Confidence Interval	p-value°	Adjusted Relative Risk (aRR)*	95% Confidence Interval	p-value°
Post-natal hydrocortisone exposure		2.20	(1.60, 3.03)	< .001	1.51	(0.91, 2.52)	0.114
Small for Gestational Age		0.72	(0.69, 0.76)	< .001	0.96	(0.84, 1.09)	0.509
Birth weight (grams)		0.99	(0.997, 0.998)	< .001	0.99	(0.99, 1.00)	0.143
Apgar	1 minute	0.85	(0.80, 0.91)	< .001	0.99	(0.90, 1.09)	0.886
Apgar	5 minutes	0.85	(0.80, 0.90)	< .001	1.03	(0.91, 1.18)	0.607
Adrenal insufficiency		3.11	(2.34, 4.12)	< .001	1.07	(0.62, 1.82)	0.811
Caffeine		7.00	(2.64, 18.53)	< .001	1.12	(0.38, 3.27)	0.835
Hypotension		4.21	(3.17, 5.59)	< .001	1.53	(1.08, 2.17)	0.018
Patient ductus arteriosus		4.81	(3.30, 7.03)	< .001	1.66	(1.12, 2.46)	0.011
Sepsis		3.97	(3.00, 5.24)	< .001	1.50	(1.07, 2.10)	0.018
Mechanical ventilation		11.52	(5.74, 23.13)	< .001	3.79	(1.74, 8.29)	< .001
Necrotizing enterocolitis		2.33	(1.68, 3.23)	< .001	1.33	(0.80, 2.21)	0.277
Nephrotoxic medication exposure		7.10	(3.19, 15.79)	< .001	1.73	(0.74, 4.07)	0.209
Legend: *Controlled for small for gestational age, birthweight, Apgar scores, death prior to discharge, hypotension, patent ductus arteriosus, sepsis, and mechanical ventilation. °P-values from bivariate and multivariate generalized mixed modeling.

This study is the largest study to date evaluating associations between PNS and AKI in VLBW neonates. In the current study we show that PNS exposure and AKI occur commonly in this population. Furthermore, we show that in our cohort, PNS is associated with an increased incidence of AKI. An interesting finding is that this association was reversed when HC was evaluated separately. These results highlight the need for further study evaluating the impact of PNS on the incidence of AKI and associated outcomes.

AKI is a common occurrence in the NICU and associated with increased morbidity and mortality in critically ill neonates. AKI prevalence in infants born extremely prematurely is as high as 48% [1]. These same extremely premature neonates who are at high risk for AKI frequently are exposed to PNS which could impact kidney health. In the current study we sought to address this knowledge gap by examining associations between PNS and neonatal AKI using a large cohort of VLBW neonates cared for in a NICU with protocolized AKI care. Our findings add to the findings of prior studies of neonatal AKI [18]. Our findings corroborate those of other investigators; we found neonatal AKI is significantly more common in infants with lower GA, BW, and APGAR scores, and independent risk factors for AKI in our cohort included hypotension, PDA, sepsis, and mechanical ventilation. Our novel findings include PNS exposure association with a 1.72-fold increased adjusted relative risk of developing AKI in our cohort, which was contrary to our hypothesis. We also found that infants with AKI were significantly more likely to have AI formally diagnosed than those without AKI though we note that AI could certainly have gone undiagnosed in many in our cohort, particularly in those to whom PNS were prescribed. However, in multivariable analysis, this association did not remain. Lastly, in performing a sub-analysis on HC exposure and associations with AKI, we detected a protective association between HC exposure and AKI; however, after controlling for significant confounders, this association was no longer present.

Our hypothesis that PNS exposure is associated with decreased incidence of AKI was based on both the findings of Baserga et al. and the underlying physiology of relative or transient AI [11]. Baserga et al. investigated late-onset glucocorticoid-responsive circulatory collapse (LCC) in VLBW infants, an event characterized by sudden onset hypotension and/or oliguria after 7 days of life, which is resistant to volume expanders and inotropes but responds rapidly to intravenous glucocorticoids. They found that 27 of 230 (11.7%) infants with LCC developed AKI, and all of these infants had resolution of their symptoms within 24 hours after initiation of HC, concluding that relative AI in these infants could be the cause of their AKI. Fofi et al. described the importance of the renin-angiotensin-aldosterone system (RAAS) in renal homeostasis and the role that RAAS disruption may play in the development of AKI in adult patients. In patients with AI, a combination of low aldosterone levels causing hypovolemia and low cortisol levels leading to decreased tone of the efferent renal arterioles with subsequent reduced perfusion pressure could together lead to AKI [19]. Although not reported, logic suggests that this mechanism would apply to preterm infants as well. Extremely preterm neonates likely also have an immature hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is functional in the fetus by 20 weeks of gestation but does not fully mature until after 30 weeks of gestation. The administration of exogenous glucocorticoids suppresses cortisol production and secretion of cortisol through negative feedback on this immature HPA axis, potentially leading to suppression of this HPA axis and subsequent AI [20].

Our findings did not support our hypothesis. Rather than being protective against AKI, we found that PNS exposure is independently associated with increased risk of AKI development. We suspect the detected association between PNS exposure and AKI may be partially confounded by indication and the inclusion of multiple types of PNS, despite our efforts to control for degree of illness and AKI confounders in our analysis. Given the potential links between the RAAS pathway, the immature HPA axis and AKI in the premature infant, as discussed above, it is possible that in some cases, neonates may experience underlying undiagnosed AI; when these infants receive PNS, it may serve a renal protective effect while the infant is exposed, and AKI occurs in these infants when the steroids are discontinued leading us to detect a misleading association between PNS exposure and AKI. AI is difficult to diagnose in the premature neonate, as cortisol levels do not appear to correlate with disease severity and most infants are diagnosed based on clinical symptoms (hyponatremia, hyperkalemia, hypotension, oliguria) [21]. This may lead to an underdiagnosis of AI which may cause an under recognition of infants at risk for development of AKI post-PNS exposure which may be true in our cohort as well. Though we found a strong association between AI and risk of AKI in bivariable analysis, this association was no longer present in adjusted analysis potentially due to underdiagnosis of AI.

In a sub-analysis of associations between solely HC exposure and AKI, a protective association was found between HC exposure and AKI. However, after controlling for significant confounders, HC exposure alone was no longer associated with AKI. There are several potential reasons why we found an association with all PNS exposure, but not HC alone, and AKI. First, dexamethasone, the most common steroid in the PNS exposure group besides hydrocortisone, is 40–50 times stronger than HC and longer-acting [22], potentially creating more suppression on the HPA axis and leading to an iatrogenic AI in these infants. Second, as only 68 of 567 infants received HC, there is a potential the sample size was too small to detect an association, and with a larger sample size we may have seen the protective association between HC and AKI stand even in an adjusted analysis.

Limitations of our study include the observational and retrospective design. Intervals between serum creatinine evaluations were at provider discretion and not protocolized. Similarly, PNS prescription was at the discretion of the provider. In the absence of a more detailed understanding of the timing, indication and type of steroid administered, conclusions based on exposure can only be limited. However, given the scarcity of available literature and studies examining this association, these findings bear consideration. Though we determined that several confounding factors were associated with risk of AKI, additional confounders may exist that were not examined. Additionally, AI diagnosis was also at the discretion of the provider and can be difficult to diagnosis.

In conclusion, the current study shows that PNS exposure was associated with a 1.72-fold increased adjusted relative risk of developing AKI in our cohort. HC exposure alone was not associated with increased risk of AKI. These findings should be interpreted with caution and warrant further detailed study as the relationship between AI, PNS, and indication for PNS treatment is extraordinarily complex. In future work, it will be important to investigate both timing, type, and indication for PNS exposure when examining associations with AKI. It will be important to examine PNS dosing and duration of treatment, as well as temporal association with AKI diagnosis including if the patient was still on PNS at time of AKI and/or length of time from discontinuation to diagnosis of AKI. It may also be prudent to examine re-initiation of PNS and subsequent resolution of AKI. It will also be important to utilize consistent criteria to diagnose AI to evaluate associations more effectively.

Conflict of Interest

The authors have no conflicts of interest to declare.

Statement of Ethics

Study approval statement: This study protocol was reviewed and approved by the Medical University of South Carolina Institutional Review Board for Human Research, approval number Pro00107979. This study was exempt from ethics committee approval per the IRB review.

Consent to participate statement: As this was a retrospective chart review, informed consent was not required. This study was granted an exemption from requiring written informed consent per the MUSC IRB committee.

Data Availability Statement

These data are not publicly available due to IRB limitations.

Funding Sources

This project was funded in part by the David and Laura Stone Endowment for Advancement in Neonatal Medicine, Division of Neonatology, Medical University of South Carolina. This funding assisted in providing compensation for our biostatistician.

Author Contributions

Cassandra Coleman contributed to the conception and design of this work, the acquisition, analysis and interpretation of the data, drafted and revised the manuscript, approved the final version, and agrees to be accountable for all aspects of the working in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Jeffrey King made substantial contributions to the acquisition of data for the work, revising it critically for important intellectual content, approved the final version, and agrees to be accountable for all aspects of the work.

David Selewski made substantial contributions to the conception and design of the work, the analysis and interpretation of data for the work, revising the work critically for important intellectual content, approved the final version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Jill Newman contributed to the design of the work, the analysis and interpretation of the data for the work, revised the work for important intellectual content, approved the final version, and agrees to be accountable for all aspects of the work.

Heidi J. Steflik contributed to conception and design of the work, analysis and interpretation of the data, critical revision for important intellectual content of this manuscript, approved the final version, and agrees to be accountable for all aspects of the work.

Acknowledgement

We would like to thank Dr. Austin Rutledge for providing information and resources in regard to the association between adrenal insufficiency, AKI, and very preterm neonates.

Jetton J BL, Sethi S, Wazir S, Rohatgi S, Soranno D, Chishti A, et al. Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study. Lancet Child Adolscent Health. 2017;1(3):184–94.
Chaturvedi S HNK, Mammen C. The path to chronic kidney disease following acute kidney injury: a neonatal perspective. Pediatric Nephrology. 2017;32:227–41.
Charlton J GR. Neonatal Acute Kidney Injury: Diagnosis, Exposures, and Long-term Outcomes. NeoReviews. 2018;19(6):e322-e36.
Ryan D SM, Flores TJ, Kent AL, Dahlstrom JE, Puelles VG, et al. Development of the Human Fetal Kidney from Mid to Late Gestation in Male and Female Infants. EBioMedicine. 2018;27:275–83.
Askenazi D HP, Schmicker R, Griffin R, Brophy P, Juul S, et al. Prevalence of acute kidney injury (AKI) in extremely low gestaional age neonates (ELGAN). Pediatric Nephrology. 2020;2020(35):9.
Stoops C, Boohaker L, Sims B, Griffin R, Selewski DT, Askenazi D. The association of intraventricular hemorrhage and acute kidney injury in premature infants from the Assessment of the Worldwide Acute Kidney Injury Epidemiology in Neonates (AWAKEN) study. Neonatology. 2019;116(4):321–30.
Adcock B, Carpenter S, Bauer J, Giannone P, Schadler A, Chishti A, et al. Acute kidney injury, fluid balance and risks of intraventricular hemorrhage in premature infants. J Perinatol. 2020;40(9):1296–300.
Al-Mouqdad MM, Huseynova R, Khalil TM, Asfour YS, Asfour SS. Relationship between intraventricular hemorrhage and acute kidney injury in premature infants and its effect on neonatal mortality. Sci Rep. 2021;11(1):1–8.
Starr MC, Boohaker L, Eldredge LC, Menon S, Griffin R, Mayock DE, et al. Acute kidney injury and bronchopulmonary dysplasia in premature neonates born less than 32 weeks' gestation. Am J Perinatol. 2020;37(03):341–8.
Askenazi D, Patil NR, Ambalavanan N, Balena-Borneman J, Lozano DJ, Ramani M, et al. Acute kidney injury is associated with bronchopulmonary dysplasia/mortality in premature infants. Pediatr Nephrol. 2015;30:1511–8.
Baserga M WK, Bergstrom B, Chan B. Late-Onset Glucocorticoid-Responsive Circulatory Collapse (LCC). Pediatric Academic Society; Baltimore, MD2019.
Fenton TR KJ. A systematic review and meta-analysis to revise the Fenton Growth chart for preterm infants. BMC Pediatrics. 2013;13(59).
Stoops C SS, Evans E, Dill L, Henderson T, Grriffin R, Goldstein S, et al. Baby NINJA (Nephrotoxic injury negated by just-in-time action): Reduction of nephrotoxic medication-associated acute kidney injury in the neonatal intensive care unit. Journal of Pediatrics. 2019;215:223–8.
PA Harris RT, BL Minor, V Elliott, M Fernandez, L O'Neal, L McLeod, et al., REDCap Consortium The REDCap consortium: Building an international community of software partners. J Biomed Inform. 2019.
PA Harris RT, R Thielke, J Payne, N Gonzalez, JG Conde. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
Zappitelli M AN, Askenazi D, Moxey-Mims M, Kimmel P, Star R, Abitbol C, et al. Developing a neonatal acute kidney injury research definition: a report from the NIDDK neonatal AKI workshop. Pediatric Research. 2017;82:569–73.
von Elm E AD, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573–7.
Jetton J AD. Acute Kidney Injury in the Neonate. Clinics in Perinatology. 2014;41(3):487–502.
Fofi C, Maresca B, Altieri S, Menè P, Festuccia F. Renal involvement in adrenal insufficiency (Addison disease): can we always recognize it? Intern Emerg Med. 2020;15(1):23–31.
Justin B. Josephsen BMH, Connie D. Anderson, Brett M. Hemmann, Paula M. Buchanan, Howard L. Williams, Lisa M. Lubsch, et al. Presumed adrenal insufficiency in neonates treated with corticosteroids for the prevention of bronchopulmonary dysplasia. Journal of Perinatology. 2022;42:65–71.
Prelipcean I WJ, Thompson L, Burchfield DJ, James-Woodley L, Chase PB, et al. Absence of relationship between serum cortisol and critical illness in premature infants. Arch Dis Child Fetal Neonatal Ed. 2021;106:408–12.
Roger J. Zoorob DC. A Different Look at Corticosteroids. American Family Physician. 1998;58(2):443–50.

There is NO conflict of interest to disclose.

Download PDF

Journal Publication

published 23 May, 2024

Read the published version in Journal of Perinatology →

Editorial decision: revise
25 Jan, 2024
Review #2 received at journal
23 Jan, 2024
Reviewer #2 agreed at journal
09 Jan, 2024
Review #1 received at journal
02 Jan, 2024
Reviewer #1 agreed at journal
19 Dec, 2023
Reviewers invited by journal
07 Dec, 2023
Submission checks completed at journal
07 Dec, 2023
Editor assigned by journal
06 Dec, 2023
First submitted to journal
06 Dec, 2023

You are reading this latest preprint version

Post-natal Steroid Exposure in Very Low Birthweight Neonates and Associations with Acute Kidney Injury

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Materials/Subjects and Methods

Study Population

Data Collection

Exposure: Post-natal Corticosteroids

Outcome: Neonatal Acute Kidney Injury

Statistical Analysis

Results

Subject Selection

Postnatal Steroid Exposure

Acute Kidney Injury

Association between Postnatal Steroid Exposure and Acute Kidney Injury

Sub-Analysis: Association between Hydrocortisone Exposure and Acute Kidney Injury

Discussion

Declarations

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1